Salivary gland tissue chip screening identifies candidate radioprotective drugs
This body of work demonstrates the development and validation of assays using a tissue chip platform for high-content drug screening and the successful discovery and in vivo validation of candidate radioprotective drugs with non-antioxidant primary modes of action. These results point to possible unknown mechanisms of radioprotection. These drugs can be developed to improve radioprotection efficacy and clinical administration without adverse side-effects.
Authors
- Danielle S. W. Benoit (ORCID: https://orcid.org/0000-0001-7137-8164)
- Jared A. Mereness (ORCID: https://orcid.org/0000-0001-9621-5580)
- Lisa A. DeLouise (ORCID: https://orcid.org/0000-0001-9399-5112)
- Paul M. Dunman (ORCID: https://orcid.org/0000-0001-5138-521X)
- Catherine E. Ovitt (ORCID: https://orcid.org/0000-0002-8045-3119)
- Lindsay Piraino (ORCID: https://orcid.org/0000-0002-8503-9558)
- Chiao‐Yun Chen (ORCID: https://orcid.org/0000-0003-4113-2547)
Institutions
- University of Oregon (US)
- University of Rochester Medical Center (US)
- University of Rochester (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1038/s43856-025-01136-7
- Citations
- 1
- Primary Topic
- Effects of Radiation Exposure
- Type
- article
- Field-Weighted Citation Impact
- 1.36